Literature DB >> 16735150

Pharmacodynamics: relation to antimicrobial resistance.

Michael J Rybak1.   

Abstract

Antibiotic pharmacodynamics (PD) describes the impact of an antimicrobial agent on a target pathogen and is based on the drug's pharmacokinetics (PK) and microbiologic activity toward that pathogen, together with the pathogen's susceptibility to the drug. Patient or host factors play an important role in antibiotic PD by affecting drug PK and patient susceptibility to infection. The 3 PD parameters commonly used to predict antibiotic efficacy are (1) the ratio of maximum serum concentration to the minimum inhibitory concentration (MIC) (C(max)/MIC); (2) the ratio of the area under the plasma concentration versus time curve (AUC) versus MIC (AUC/MIC) and (3) the duration of the dosing interval that plasma concentrations exceed the MIC (T>MIC). The C(max)/MIC ratio has been shown to predict aminoglycoside efficacy, AUC/MIC best describes fluoroquinolone, glycopeptide, and ketolide efficacy, and T>MIC best describes the efficacy of beta-lactams and macrolides. Traditionally, PK and PD (PK/PD) parameters have been used to predict antibiotic efficacy, but there is now increasing interest in trying to use PK/PD parameters to minimize development of resistance. With respect to fluoroquinolone resistance, the "mutant selection window" hypothesis has been developed to describe how drug exposures below the mutant prevention concentration may create conditions for the selection of resistant bacterial strains. The AUC/MIC ratio has also been used to describe fluoroquinolone drug exposures associated with either increased or decreased risk of resistance emergence. The accessory gene regulator (agr) locus in Staphylococcus aureus--and particularly agr group II--has been associated with reduced susceptibility or resistance of S aureus to vancomycin. Recent experiments suggest that the AUC/MIC ratio may be used to identify vancomycin exposures associated with emergence of resistance in S aureus. More generally, AUC/MIC ratios may be additive, and combination therapies may represent 1 approach to lowering the emergence rate of bacterial resistance associated with antibiotic therapy. But, further work needs to be done before this conclusion can be verified.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16735150     DOI: 10.1016/j.amjmed.2006.04.001

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  21 in total

1.  Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model.

Authors:  Anthony M Nicasio; Jürgen B Bulitta; Thomas P Lodise; Rebecca E D'Hondt; Robert Kulawy; Arnold Louie; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

2.  Drug interactions modulate the potential for evolution of resistance.

Authors:  Jean-Baptiste Michel; Pamela J Yeh; Remy Chait; Robert C Moellering; Roy Kishony
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-24       Impact factor: 11.205

3.  Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.

Authors:  Jill M Butterfield; Nimish Patel; Manjunath P Pai; Thomas G Rosano; George L Drusano; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

4.  Antibiotic administration in the drinking water of mice.

Authors:  James O Marx; Daljit Vudathala; Lisa Murphy; Shelley Rankin; F Claire Hankenson
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-05       Impact factor: 1.232

5.  Antimicrobial Stewardship in Laboratory Animal Facilities.

Authors:  Heather L Narver
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-01-01       Impact factor: 1.232

6.  Modeling the response of a biofilm to silver-based antimicrobial.

Authors:  A E Stine; D Nassar; J K Miller; C B Clemons; J P Wilber; G W Young; Y H Yun; C L Cannon; J G Leid; W J Youngs; A Milsted
Journal:  Math Biosci       Date:  2013-04-27       Impact factor: 2.144

7.  Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.

Authors:  Jack Brown; Kristen Brown; Alan Forrest
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

8.  Systemic antimicrobial therapy in osteomyelitis.

Authors:  Henry S Fraimow
Journal:  Semin Plast Surg       Date:  2009-05       Impact factor: 2.314

Review 9.  Optimizing the Clinical Use of Vancomycin.

Authors:  Rocío Álvarez; Luis E López Cortés; José Molina; José M Cisneros; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

10.  Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants.

Authors:  Yewei Chen; Dan Wu; Min Dong; Yiqing Zhu; Jinmiao Lu; Xiaoxia Li; Chao Chen; Zhiping Li
Journal:  Eur J Clin Pharmacol       Date:  2018-03-30       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.